A Single Arm, Multicenter, Phase IIa Study to Explore the Efficacy and Safety of Ruxolitinib (INC424) in Regularly Transfused Patients With Thalassemia

Trial Profile

A Single Arm, Multicenter, Phase IIa Study to Explore the Efficacy and Safety of Ruxolitinib (INC424) in Regularly Transfused Patients With Thalassemia

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Thalassaemia
  • Focus Therapeutic Use
  • Acronyms TRUTH
  • Sponsors Novartis
  • Most Recent Events

    • 06 Dec 2016 Results of a single-arm, multicenter, phase 2a Truth study, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 04 May 2016 Status changed from active, no longer recruiting to completed.
    • 26 Jan 2016 Planned End Date changed from 1 May 2016 to 1 Apr 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top